Celcuity Completes $201.25 Million Convertible Notes Issuance

Celcuity ( (CELC) ) has issued an announcement.

On July 30, 2025, Celcuity Inc. entered into an underwriting agreement with several underwriters to issue and sell $175 million in Convertible Senior Notes, with an additional option exercised for $26.25 million, resulting in a total issuance of $201.25 million completed on August 1, 2025. The proceeds, approximately $194.5 million after expenses, are intended for working capital and general corporate purposes, including research and development and business expansion. The Notes, maturing in 2031, are convertible into common stock and include provisions for redemption and conversion adjustments based on market conditions.

The most recent analyst rating on (CELC) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Celcuity stock, see the CELC Stock Forecast page.

Spark’s Take on CELC Stock

According to Spark, TipRanks’ AI Analyst, CELC is a Neutral.

Celcuity’s stock score of 43.73 reflects the challenges faced by early-stage biotech firms. The company’s financial performance is weak due to lack of revenue and high expenses. Technical analysis shows a neutral to slightly negative outlook, while valuation metrics are poor due to negative earnings. Despite these challenges, the earnings call provided a positive outlook with potential future revenue and strong financial positioning. The overall score indicates significant risks but potential for future growth if clinical and financial milestones are achieved.

To see Spark’s full report on CELC stock, click here.

More about Celcuity

Average Trading Volume: 865,817

Technical Sentiment Signal: Buy

Current Market Cap: $1.52B

See more insights into CELC stock on TipRanks’ Stock Analysis page.